PREMARIN Tablets 2.5 Milligram

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

ESTROGENS CONJUGATED

Available from:

John Wyeth & Brother Limited

Dosage:

2.5 Milligram

Pharmaceutical form:

Tablets

Authorization date:

1988-07-25

Summary of Product characteristics

                                IRISH MEDICINES BOARD ACT 1995
MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998
(S.I. NO.142 OF 1998)
PA0022/058/005
Case No: 2026843
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
JOHN WYETH & BROTHER LIMITED
HUNTERCOMBE LANE SOUTH, TAPLOW, MAIDENHEAD, BERKSHIRE SL6 0PH, UNITED KINGDOM
an authorisation, subject to the provisions of the said Regulations, in respect of the product
PREMARIN 2.5 MILLIGRAM TABLETS
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 24/11/2006 until 24/07/2008.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 25/11/2006_
_CRN 2026843_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Premarin* Tablets 2.5mg.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 2.5 mg conjugated estrogens.
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Tablet.
Purple, oval, biconvex, sugar coated tablets.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Premarin is indicated for hormone replacement therapy (HRT) for estrogen deficiency symptoms in menopausal
women and postmenopausal women.
Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or
contraindicated for, other medicinal products approved for the prevention of osteoporosis.
(S
                                
                                Read the complete document